Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer

传染病和癌症疫苗和免疫疗法培训补助金

• 批准号: 10465086
• 负责人: Matthias Johannes Schnell
• 金额: $ 16.49万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10465086
• 关键词: Communicable Diseases; Grant; Immunotherapy; Malignant Neoplasms; Training; Vaccines

Summary This is a new application that proposes a training program for 3 graduate students and 2 postdoctoral fellows in vaccines and immunotherapies against microbial pathogens and cancer. The rationale for this application is to capitalize on the long-term experience of TJU in the area of vaccines, therapeutics and cancer, the need for a such a unique training opportunity in Philadelphia, and the opportunity to develop a “holistic” training experience in both basic and applied aspects of viral and tumor immunity. An important characteristic of the TPVIIDC is that the diversity of research interests of the 21 preceptors affords an opportunity to provide a comprehensive training experience that integrates basic science, vaccine development and therapeutics. Whereas there are other training programs in cancer immunology or vaccines against infectious diseases there is historically little cross-talk between these highly related research areas. We feel strongly that our program will help to provide better training by providing opportunities in different but related areas of immunology of cancer and infectious diseases. While the students and fellows will spend the majority of their time in their host laboratory, ancillary opportunities will enable interaction with a wide range of the participating faculty, facilitated by shared seminars, retreats and course offerings.

概括 这是一个新的应用程序，建议针对3名研究生和2个 疫苗和针对微生物病原体和癌症的免疫疗法中的博士后研究员。 该应用程序的理由是利用该地区TJU的长期经验 疫苗，疗法和癌症，需要在这种独特的培训机会中 费城，以及在基本和 病毒和肿瘤免疫学的应用方面。 TPVIIDC的一个重要特征是 21个受体的研究兴趣的多样性为提供一个提供机会 综合培训经验，将基础科学，疫苗开发和 治疗。癌症免疫学或疫苗中还有其他培训计划 反对感染性疾病，这些高度相关的人在历史上几乎没有交叉讲话 研究领域。我们强烈认为我们的计划将有助于提供更好的培训 在癌症和感染性免疫学的不同但相关领域提供机会 疾病。而学生和研究员将大部分时间都花在主持人中 实验室，辅助机会将使参与的广泛互动 教师，由共享的半手，务虚会和课程提供。

项目成果

Oral D-mannose treatment suppresses experimental autoimmune encephalomyelitis via induction of regulatory T cells.

• DOI: 10.1016/j.jneuroim.2021.577778
• 发表时间: 2022-01-15
• 期刊: Journal of neuroimmunology
• 影响因子: 3.3
• 作者: Hwang D;Boehm A;Rostami A;Zhang GX;Ciric B
• 通讯作者: Ciric B

GATA1 controls numbers of hematopoietic progenitors and their response to autoimmune neuroinflammation.

• DOI: 10.1182/bloodadvances.2022008234
• 发表时间: 2022-12-13
• 期刊: BLOOD ADVANCES
• 影响因子: 7.5
• 作者: Hwang, Daniel;Ishikawa, Larissa Lumi Watanabe;Seyedsadr, Maryam S.;Mari, Elisabeth;Kasimoglu, Ezgi;Sahin, Ziver;Boehm, Alexandra;Jang, Soohwa;Rasouli, Javad;Vaccaro, Courtney;Gonzalez, Michael;Hakonarson, Hakon;Rostami, Abdolmohamad;Zhang, Guang-Xian;Ciric, Bogoljub
• 通讯作者: Ciric, Bogoljub

CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation.

• DOI: 10.1073/pnas.2111804119
• 发表时间: 2022-04-05
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1